Susanne Merkel
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial
Golcher H, Fietkau R, Merkel S, Meyer T, Grabenbauer G, Schreiber S, Jungnickel H, Bruns C, Bechstein W, Marti L, Witzigmann H, Brunner T, Hohenberger W. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol 2014; 191:7-16.
25.09.2014Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial
25.09.2014Strahlenther Onkol 2014; 191:7-16
Golcher Henriette, Fietkau Rainer, Merkel Susanne, Meyer Thomas, Grabenbauer Gerhard G, Schreiber Stefan, Jungnickel Henry, Bruns Christiane, Bechstein Wolf-Otto, Marti Lukas, Witzigmann Helmut, Brunner Thomas B, Hohenberger Werner
p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors
Wassermann S, Kirchner T, Brabletz T, Merkel S, Reu S, Kriegl L, Haynl A, Hlubek F, Horst D, Palmqvist R, Hiendlmeyer E, Scheel S, Jung A. p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors. Gastroenterology 2009; 136:196-205.e2.
01.01.2009p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors
01.01.2009Gastroenterology 2009; 136:196-205.e2
Wassermann Stella, Kirchner Thomas, Brabletz Thomas, Merkel Susanne, Reu Simone, Kriegl Lydia, Haynl Angela, Hlubek Falk, Horst David, Palmqvist Richard, Hiendlmeyer Elke, Scheel Silvio K, Jung Andreas